Charles River Laboratories | CRL - Gross Profit On Sales


Charles River Laboratories reported $348.78M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Agilent USD 990M 44M Mar/2026
Align Technology USD 757.43M 20.84M Jun/2026
Bio-Rad Laboratories USD 309.4M 35.8M Mar/2026
Bruker USD 416M 36.2M Jun/2026
Cardinal Health USD 2.5B 101M Mar/2026
Charles River Laboratories USD 348.78M 69.47M Jun/2026
Cigna USD 6.08B 50.37B Mar/2026
Concord Medical Services Hldg CNY -37.42M 26.25M Jun/2023
CVS Health USD 15.75B 125M Jun/2026
Danaher USD 3.61B 20M Jun/2026
Dentsply International USD 493M 66M Jun/2026
Elevance Health USD 44.33B 32.65B Jun/2026
Humana USD 4.82B 754M Jun/2025
Illumina USD 770M 49M Jun/2026
Incyte USD 1.57B 400.89M Jun/2026
Intrexon USD -297K 167K Jun/2024
IQVIA Holdings USD 1.44B 368M Jun/2026
Laboratory Of America USD 1.11B 98.2M Jun/2026
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
McKesson USD 3.68B 359M Jun/2026
Merck EUR 3.07B 104M Mar/2026
Mettler Toledo International USD 555.82M 119.62M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Quest Diagnostics USD 906M 33M Mar/2026
Revvity USD 416.87M 29.21M Jun/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
United Therapeutics USD 683.8M 35.7M Jun/2026
UnitedHealth USD 98.66B 73.25B Jun/2026
Veradigm USD 83.44M 3.95M Sep/2022
Waters USD 490M 52M Jun/2026
West Pharmaceutical Services USD 296.4M 7.5M Mar/2026